Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th
May 16 2022 - 8:55AM
Artelo Biosciences, Inc. “Artelo” or the
“Company”) (NASDAQ: ARTL), a clinical stage pharmaceutical
company developing therapeutics that modulate lipid-signaling
pathways, including the endocannabinoid system, today announced
that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be
presenting at the H.C. Wainwright Global Investment Conference
which is being held on May 23- May 26, 2022 at the Fontainebleau
Miami Beach Hotel, Miami FL. The conference will include virtual
and in-person participation.
Mr. Gorgas is scheduled to present in-person on
Tuesday, May 24, 2022 at 5:00 p.m. ET. The presentation will be
webcast live and available for replay at
https://journey.ct.events/view/aa6377fb-fc77-4015-9e7b-a3873bcc0c33.
Management will also be available for one-on-one meetings with
qualified investors throughout the conference.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage
pharmaceutical company dedicated to the development and
commercialization of proprietary therapeutics that modulate
lipid-signaling pathways, including the endocannabinoid system.
Artelo is advancing a portfolio of broadly applicable product
candidates designed to address significant unmet needs in multiple
diseases and conditions, including anorexia, cancer, PTSD, pain,
and inflammation. Led by proven pharmaceutical executives
collaborating with highly respected researchers and technology
experts, Artelo applies leading edge scientific, regulatory, and
commercial discipline to develop high-impact therapies. More
information is available at www.artelobio.com and
Twitter: @ArteloBio.
Forward Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to Artelo’s product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies,
potential growth opportunities and other statement that are
predictive in nature. These forward-looking statements are based on
current expectations, estimates, forecasts and projections about
the industry and markets in which we operate and management’s
current beliefs and assumptions. These statements may be identified
by the use of forward-looking expressions, including, but not
limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,”
“estimate,” “potential,” “predict,” “project,” “should,” “would”
and similar expressions and the negatives of those terms. These
statements relate to future events or our financial performance and
involve known and unknown risks, uncertainties, and other factors
which may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Such factors include those set forth in Artelo’s
filings with the Securities and Exchange Commission, including our
ability to raise additional capital in the future. Prospective
investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this
press release. Artelo undertakes no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events or otherwise, except to the extent
required by applicable securities laws.
Investor Relations
Contact:Crescendo Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024